US007 179493B2 (12) United States Patent (10) Patent No.: US 7,179,493 B2 Ellison et al. (45) Date of Patent: Feb. 20, 2007 (54) COMPOSITIONS AND METHODS FOR THE 6,770,304 B2 8/2004 Warrel, Jr. et al. TREATMENT OF PRIMARY AND 2005/0196464 A1* 9, 2005 Hu et al. .................... 424,623 METASTATC NEOPLASTIC DISEASES USING ARSENC COMPOUNDS FOREIGN PATENT DOCUMENTS (75) Inventors: Ralph M. Ellison, Palm Beach, FL (US); Fred H. Marmelstein, Clifton, CN 1061908 A 6, 1992 NJ (US) CN 1079.391 A 12/1993 CN 1081104. A 1, 1994 (73) Assignee: Polarx Biopharmaceuticals, Inc., CN 1119113 A 3, 1996 Wilmington, DE (US) CN 1121807 A 5, 1996 CN 1122700 A 5, 1996 (*) Notice: Subject to any disclaimer, the term of this CN 1131037 A 9, 1996 patent is extended or adjusted under 35 CN 1133725 A 10, 1996 U.S.C. 154(b) by 438 days. JP 51-88620 3, 1976 WO WO 94,02108 2, 1994 (21) Appl. No.: 10/649,776 WO WO95/O1789 1, 1995 WO WO95/22336 8, 1995 (22) Filed: Aug. 28, 2003 (65) Prior Publication Data OTHER PUBLICATIONS US 2004/O115283 A1 Jun. 17, 2004 “Arsen (III)—Sulfid AS.S.", Gmelin's Arsenic 8". Edition, 17:422 433, 1952. Related U.S. Application Data “Diarsendisulfid AS.S.", Gmelin's Arsenic, 8". Edition, 17:412 (62) Division of application No. 09/173,531, filed on Oct. 422, 1952. 15, 1998, now Pat. No. 6.875451. "Goodman & Gilman's The pharmacological basis of therapeutics'. s s s s 9" Edition, McGraw-Hill, Health Professions Division, pp. 1659 (60) Provisional application No. 60/062.375, filed on Oct. 1662, date unknown. 15, 1997. “Inorganic Arsenic Compounds. Other Than Arsine Health and Safety Guide, Health and Safety Guide No. 70', WHO, Geneva, (51) Int. Cl. 1992. A6 IK33/36 (2006.01) 'Xionghuang Realgar'. Chinese Pharmacopia (1), Guangdong Sci A6 IK 33/24 (2006.01) ence and Technology Publishing House, China, pp. 298-299, 1995. A6 IK 9/00 (2006.01) Akao et al. "Arsenic Induces Apoptosis in B-cell Leukemic Cell A6 IK3I/28 (2006.01) Lines in Vitro. Activation of Caspases and Down-regulation of A6 IK3I/282 (2006.01) Bcl-2 Protein', British J of Hematology, 102. 1055-1060, 1998. A6 IK3I/33 (2006.01) Andre et al., “The PML and PML/RARI Domains: from autoim munity to molecular oncology and from retinoic acid to arsenic'. A 6LX 3/555 (2006.01) Experimental Cell Research, 229:253-260, 1996. St. t%% 3. Arsenic, Environmental Health Criteria 18, Geneva: WHO, 1981. / ( .01) Chemical Abstract, 63-Pharmaceuticals 11:317, #111:219272 and A61 P 35/02 (2006.01) 111:219276p, 1987-1991. (52) U.S. Cl. .................. 424/623; 424/85.1; 424/184.1; 424/277.1; 424/278.1; 424/620: 424/629; (Continued) 424/649; 514/2: 514/8: 514/12: 514/21: 514/23; Pri E John Pak 514/25; 514/27: 514/28: 514/29:514/34: 514/31;514/45 (74)AST Attorney, 'Can Agent, orO FiFirm—Cephalon, a Cephalon. Inc.I (58) Field of Classification Search ................ 424/422, (57) ABSTRACT 424/620, 623,629, 649, 184.1, 277.1, 85.1 424/278.1: 514/2, 8, 12, 21, 23, 25, 27–29, 514/31, 34, 45, 49,90, 110, 171, 183-185, The invention relates to the use of arsenic compounds to 514/249, 274, 283,444, 449, 492, 504, 588, treat a variety of neoplastic diseases. The present invention 514/615, 733, 50, 109, 251, 559, 575; 600/1 encompasses the administration to a mammal of arsenic in See application file for complete search history. the form of a salt, complex, organic compound or ionic (56) References Cited Solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoi U.S. PATENT DOCUMENTS etic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic 132,275 A 10/1872 Gettings 232,807 A 10, 1880 Dennett disorders in mammals by the administration of one or more 3,700.498 A 10, 1972 Kanazawa et al. arsenic compounds to said mammal. Further, the arsenic 4497,780 A 2f1985 Barin et al. compounds may be used to treat metastatic neoplastic dis 5,759,837 A 6/1998 Kuhajda et al. CaSCS. 6,720,011 B1 4/2004 Zhang 6,733,792 B1 5, 2004 Lu 9 Claims, 12 Drawing Sheets US 7,179,493 B2 Page 2 OTHER PUBLICATIONS Qi and Bi, “Method for removing ASO, from Realgar'. Chung Yao Tung Pao, 8(5):21-22, 1983. Chen et al., “In vitro studies on cellular and molecular mechanisms Reichlet al., “Effect of Arsenic on Cellular Metabolism after Single of arsenic trioxide (ASO) in the treatment of acute promyelocytic or Repeated Injection in Guinea Pigs'. Arch. Toxicol. Suppl. 13. p. Leukemia: ASO induces NB cell apoptosis with down regulation 363-65, 1989. of Bcl-2 expression and modulation of PML-RARIPML proteins”. Remington's Pharmaceutical Sciences, Mach Publishing Co., Blood 88(3): 1052-1061, 1996. Chen et al., “Use of Arsenic Trioxide (ASO) in the Treatment of Easton, PA, p. 1570-80, 1990. Acute Promyelocytic Leukemia (APL):I. AsO. Exerts Dose-De Schenk, Handbook of Preparative Inorganic Chemistry, 1:603, G. pendent Dual Effects on APL Cells” Blood 89(9):3345-3353, 1997. Brauer, Ed., Academic press, New York, 2" Ed. 1963. Chung et al., “Influence for Carcinoma Cell and Lymphatic cell of Shen et al., “Use of arsenic trioxide (ASO) in the treatment of Acetyl Arsonate”. Yakhak Hoeji 40(5):599-607, 1996. acute promyelocytic Leukemia (APL):II. Clinical efficacy and Cutler et al., Article IV, American Journal of the Medical Sciences, pharmacokinetics in relapsed patients”. Blood 89(9):3354-3360, pp. 74-84, date unknown. 1997. CuZicket al., “Medicinal arsenic and internal malignancies'. Br. J. Shibuya, "Studies on Experimental Arsenious Acid Poisoning”. Cancer, 45:904-911, 1982. Tokyo Jikeikai Ika Daigaku Zasshi 86(4):653, 1971. De The, "L'oxyde d'arsenic: après l'acide retinoique, un nouveau Soignet et al., “Complete Remission after Treatment of Acute traitement cible de la leucemie aigue promyelocytaire' medicine? Promyelocytic Leukemia with Arsenic Trioxide'. J of Medicine sciences; 13: 867-71, 1997. 339:19, 1998. Dictionary of Inorganic Compounds, vol. 1. Ac-Co., IC-000667 Stephens et al., “The therapeutic effect of solution of potassium IC-000671, date unknown. arsenite in chronic myelogenous leukemia Ann. Intern. Assoc Flamigni et al., “Effect of Sodium Arsenite on the Induction and 9:1488-1502, 1936. Turnover of Omithine Decarboxylase Activity in Erythroleukemia Suehiro Shimotsuura et al., “Studies on the Antineoplasmic Actions Cells” Cell Biochemistry and Function 7:213-217, 1989. of AsO., Shikwa Gakuho 86:1237-1253, 1986. Fluka, 1995/96 Catalog: 152-153. Sun et al., "Ai Ling #1 and Traditional Chinese Medicine in the Forkner et al., “Arsenic as a therapeutic agent in chronic Treatment of 32 patients with Acute Promyelocytic Leukemia', myelogenous leukemia', Jour. A.M.A. 97(1)3-5, 1931. Chinese J. of Traditional Chinese and Western Medicine 1(3), 1992. Germolec et al., “Arsenic induces over expression of growth factors Treleaven et al., “Arsenic and Ayurveda Leukemia and Lymphoma in human keratinocytes'. Toxicology and Applied Pharmacology, 10:343-345, 1993. 141:308-318, 1996. USP Dictionary of USAN and Intenrational Drug Names, United Huang et al., 1995, “The Clinical Study of QINGDAI Tablet For States Pharcopeial Conventions, Inc. Rockville, MD, p. 59, Nov. Treating Acute Promyelocytic Leukemia' China Magazine of 1994. Hematology, 16(1):26. Wang et al., “Arsenic and the Treatment of Leukemia', J. Harbin Ishinishi N. et al., “Study on Chronic Toxicity of Arsenic Trioxide Medical Univ. 31:5 428-429, 1997. in Rats with Special Reference to the Liver Damages'Fukuok Acta Wang et al., “Studies on chemically preventing Leukemia. Chung Medicine, 71:27, 1980. Hua Chung Liu Tsa Chih, 11(3):207-210, 1989. Kasper et al., "Hepatic Angiosarcoma and bronchioloalveolar car Xiang et al., 1995, "60 Cases of Treating Acute Promyelocytic cinoma induced by Fowler's solution”. JAMA 252(24):3407-3408, Leukemia by QINGDAI Tablet'. Med. J. Chin. PLA2003):227-229. 1984. Yamamoto et al. "Tumorigenicity of inorganic arsenic compounds Kerkvliet et al., “Immunotoxicology Studies of Sodium Arsenate following intratracheal instillations to the lungs of hamsters'. Int. J. effects of Exposure on Tumor Growth and Cell-mediated Tumor Cancer, 40:220-223, 1987. Immunity”. J. Environment Pathology and Toxicology 4:65-79. Yuan et al., “Research on traditional methods for Purifying 1980. Realgar'. Chung Yao Tung Pao, 13(8): 23-26, 1988. Konig et al., "Comparative Activity of Melarsoprol and Arsenic Yuan et al., “Exploring methods for purifying Realgar'. Chung Yao Trioxide in Chronic B-Cell Leukemia Lines”. Blood 90(2):562-570, Tung Pao, 13(8): 17-21, 1988. 1997. Zhang et al., “Traditional Chinese and Western Medicine in the Kwong et al., “Delicious Poison: Arsenic Trioxide for the treatment Treatment of 27 patients with Malignant Lymphoma' Chinese J. of Leukemia, Blood 89:3487-8, 1997. Oncology 10:61-62, 1988. Lee et al., “Induction of Gene Amplification by Arsenic'. Science, 241: 79-81, 1988. Zhang et al. “Treatment of Acute Promyelocytic Leukemia with Li et al. “Traditional Chinese and Western Medicine in the Treat “713”; Clinical Observations and Study of Action Mode on 117 ment of 27 Patients with Malignant Lymphoma'. Chinese J. Oncol Patients”. J. Harbin Medical Univ. 29(3): 243, 1995. ogy, 10:61-62, 1988. Zhang et al., “Clinical Study on the Treatment of Acute Lu et al., “Effective treatment of AML-M3 (APL) and their remis Promyelocytic Leukemia with Ai Ling #1'.